Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Cellectis S.A. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 32 | 27 | −5 |
| Shares | 10.2M | 9.48M | −767.5K (−7.5%) |
| Value | $32.5M | $28.4M | −$4.04M (−12.4%) |
New holders (3)
Institutions that held Cellectis S.A. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Royal Bank of Canada | 1,558 | $5.00K | 0.00% |
| Caitong International Asset Management Co., Ltd | 49 | $147 | 0.00% |
| Jones Financial Companies LLLP | 50 | $142 | 0.00% |
Sold out (8)
Institutions that held Cellectis S.A. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Citadel Advisors LLC | 44,315 | $140.5K |
| Marshall Wace, LLP | 41,112 | $130.3K |
| Lido Advisors, LLC | 10,094 | $32.0K |
| Tower Research Capital LLC (TRC) | 1,797 | $5.70K |
| Quadrant Capital Group LLC | 944 | $2.99K |
| Barclays PLC | 224 | $710 |
| Group One Trading, L.P. | 97 | $307 |
| Citigroup Inc | 1 | $3 |